Patents by Inventor Corentin Herbert

Corentin Herbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9732078
    Abstract: The invention relates to the use of compounds corresponding to formula (I) in which R2 and R3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of the formulae (A), (B) and (C) in which the wavy lines represent the phenyl nucleus to which R2 and R3 are attached, or of a pharmaceutically acceptable salt thereof, for preparing a medicament for the treatment of bladder cancer.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: August 15, 2017
    Assignee: SANOFI
    Inventors: Chantal Alcouffe, Corentin Herbert
  • Patent number: 9452164
    Abstract: The invention relates to compounds corresponding to formula (I): in which R2 and R3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: in which the wavy lines represent the phenyl nucleus to which R2 and R3 are attached. Preparation process and therapeutic use.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: September 27, 2016
    Assignee: SANOFI
    Inventors: Chantal Alcouffe, Reinhard Kirsch, Corentin Herbert, Gilbert Lassalle
  • Publication number: 20160193192
    Abstract: The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.
    Type: Application
    Filed: November 30, 2015
    Publication date: July 7, 2016
    Inventors: Peter Carmeliet, Frederik De Smet, Joost Schymkowitz, Frédéric Rousseau, Corentin Herbert
  • Patent number: 9234025
    Abstract: The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: January 12, 2016
    Assignees: SANOFI, VIB VZW, LIFE SCIENCES RESEARCH PARTNERS VZW, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Peter Carmeliet, Frederik De Smet, Joost Schymkowitz, Frédéric Rousseau, Corentin Herbert
  • Patent number: 9012413
    Abstract: The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R1 is an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, R2 is an OSO3? or hydroxyl group, R3 is an alkyl, cycloalkyl, or alkyl-cycloalkyl group, R4 is a disaccharide having Formula (II), R6 is a disaccharide having Formula (III), and R8 is a disaccharide having Formula (IV), where R5, R7, and R9 are OSO3? or hydroxyl groups. The invention further relates to the preparation of said octasaccharides and to the therapeutic use thereof.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: April 21, 2015
    Assignee: Sanofi
    Inventors: Pierre Alexandre Driguez, Philippe Duchaussoy, Pierre Fons, Corentin Herbert, Gilbert Lassalle
  • Publication number: 20140343054
    Abstract: The invention relates to the use of compounds corresponding to formula (I) in which R2 and R3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of the formulae (A), (B) and (C) in which the wavy lines represent the phenyl nucleus to which R2 and R3 are attached, or of a pharmaceutically acceptable salt thereof, for preparing a medicament for the treatment of bladder cancer.
    Type: Application
    Filed: January 3, 2013
    Publication date: November 20, 2014
    Inventors: Chantal Alcouffe, Corentin Herbert
  • Patent number: 8859544
    Abstract: The invention relates to compounds corresponding to formula (I): in which R3 and R4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: in which the wavy lines represent the phenyl nucleus to which R3 and R4 are attached. Preparation process and therapeutic use.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: October 14, 2014
    Assignee: Sanofi
    Inventors: Chantal Alcouffe, Corentin Herbert, Gilbert Lassalle
  • Publication number: 20140243328
    Abstract: The invention relates to compounds corresponding to formula (I): in which R2 and R3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: in which the wavy lines represent the phenyl nucleus to which R2 and R3 are attached. Preparation process and therapeutic use.
    Type: Application
    Filed: May 1, 2014
    Publication date: August 28, 2014
    Applicant: SANOFI
    Inventors: Chantal ALCOUFFE, Reinhard KIRSCH, Corentin HERBERT, Gilbert LASSALLE
  • Patent number: 8759344
    Abstract: The invention relates to compounds corresponding to formula (I): in which R2 and R3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: in which the wavy lines represent the phenyl nucleus to which R2 and R3 are attached. Preparation process and therapeutic use.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: June 24, 2014
    Assignee: Sanofi
    Inventors: Chantal Alcouffe, Reinhard Kirsch, Corentin Herbert, Gilbert Lassalle
  • Publication number: 20130116250
    Abstract: The invention relates to compounds corresponding to formula (I): in which R2 and R3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: in which the wavy lines represent the phenyl nucleus to which R2 and R3 are attached. Preparation process and therapeutic use.
    Type: Application
    Filed: July 4, 2011
    Publication date: May 9, 2013
    Applicant: SANOFI
    Inventors: Chantal Alcouffe, Reinhard Kirsch, Corentin Herbert, Gilbert Lassalle
  • Publication number: 20130116249
    Abstract: The invention relates to compounds corresponding to formula (I): in which R3 and R4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: in which the wavy lines represent the phenyl nucleus to which R3 and R4 are attached. Preparation process and therapeutic use.
    Type: Application
    Filed: July 4, 2011
    Publication date: May 9, 2013
    Applicant: SANOFI
    Inventors: Chantal Alcouffe, Corentin Herbert, Gilbert Lassalle
  • Publication number: 20120214754
    Abstract: The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R1 is an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, R2 is an OSO3? or hydroxyl group, R3 is an alkyl, cycloalkyl, or alkyl-cycloalkyl group, R4 is a disaccharide having Formula (II), R6 is a disaccharide having Formula (III), and R8 is a disaccharide having Formula (IV), where R5, R7, and R9 are OSO3? or hydroxyl groups. The invention further relates to the preparation of said octasaccharides and to the therapeutic use thereof.
    Type: Application
    Filed: February 9, 2012
    Publication date: August 23, 2012
    Applicant: SANOFI
    Inventors: Pierre Alexandre DRIGUEZ, Philippe DUCHAUSSOY, Pierre FONS, Corentin HERBERT, Gilbert LASSALLE
  • Publication number: 20120094864
    Abstract: The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.
    Type: Application
    Filed: July 2, 2010
    Publication date: April 19, 2012
    Applicants: SANOFI, VRIJE UNIVERSITEIT BRUSSEL, LIFE SCIENCES RESEARCH PARTNERS VZW, VIB VZW
    Inventors: Peter Carmeliet, Frederik De Smet, Joost Schymkowitz, Frédéric Rousseau, Corentin Herbert
  • Publication number: 20110150903
    Abstract: The present invention relates to FGF-R4 receptor-specific antagonist molecules enabling the inhibition of the activity of said receptor. Said antagonists are, particularly, FGF-R4-specific antibodies enabling the inhibition of the activity of said receptor. The present invention also relates to the therapeutic use of said antibodies, particularly in the field of angiogenesis and in the treatment of certain types of cancer.
    Type: Application
    Filed: July 7, 2009
    Publication date: June 23, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Nicolas Baurin, Pierre-Francois Berne, Francis Blanche, Francoise Bono, Beatrice Cameron, Tarik Dabdoubi, Corentin Herbert, Vincent Mikol, Elisabeth Remy